<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p122" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_122{left:130px;bottom:1195px;letter-spacing:0.21px;}
#t2_122{left:796px;bottom:1195px;letter-spacing:0.13px;}
#t3_122{left:128px;bottom:1104px;letter-spacing:0.16px;}
#t4_122{left:238px;bottom:1104px;letter-spacing:-0.18px;}
#t5_122{left:141px;bottom:1070px;letter-spacing:-0.1px;}
#t6_122{left:250px;bottom:1070px;letter-spacing:-0.01px;}
#t7_122{left:143px;bottom:1010px;letter-spacing:-0.29px;}
#t8_122{left:250px;bottom:1030px;letter-spacing:-0.01px;}
#t9_122{left:250px;bottom:1011px;letter-spacing:-0.01px;}
#ta_122{left:248px;bottom:976px;letter-spacing:0.09px;}
#tb_122{left:238px;bottom:922px;letter-spacing:-0.01px;}
#tc_122{left:238px;bottom:902px;letter-spacing:-0.01px;}
#td_122{left:238px;bottom:883px;letter-spacing:-0.01px;}
#te_122{left:238px;bottom:854px;letter-spacing:-0.01px;}
#tf_122{left:238px;bottom:835px;letter-spacing:-0.01px;}
#tg_122{left:238px;bottom:815px;letter-spacing:-0.01px;}
#th_122{left:238px;bottom:796px;letter-spacing:-0.01px;}
#ti_122{left:238px;bottom:776px;letter-spacing:-0.01px;}
#tj_122{left:238px;bottom:709px;letter-spacing:-0.01px;}
#tk_122{left:238px;bottom:690px;letter-spacing:-0.01px;}
#tl_122{left:238px;bottom:670px;letter-spacing:-0.01px;}
#tm_122{left:238px;bottom:651px;letter-spacing:-0.01px;}
#tn_122{left:238px;bottom:631px;letter-spacing:-0.01px;}
#to_122{left:238px;bottom:612px;letter-spacing:-0.01px;}
#tp_122{left:238px;bottom:592px;letter-spacing:-0.01px;}
#tq_122{left:238px;bottom:573px;letter-spacing:-0.01px;}
#tr_122{left:238px;bottom:553px;letter-spacing:-0.01px;}
#ts_122{left:238px;bottom:534px;letter-spacing:-0.01px;}
#tt_122{left:238px;bottom:447px;letter-spacing:-0.01px;}
#tu_122{left:238px;bottom:428px;letter-spacing:-0.01px;}
#tv_122{left:238px;bottom:408px;letter-spacing:-0.01px;}
#tw_122{left:238px;bottom:389px;letter-spacing:-0.01px;}
#tx_122{left:238px;bottom:369px;letter-spacing:-0.01px;}
#ty_122{left:238px;bottom:321px;letter-spacing:-0.01px;}
#tz_122{left:238px;bottom:302px;letter-spacing:-0.01px;}
#t10_122{left:238px;bottom:282px;letter-spacing:-0.01px;}
#t11_122{left:238px;bottom:263px;letter-spacing:-0.01px;}
#t12_122{left:238px;bottom:244px;letter-spacing:-0.01px;}
#t13_122{left:238px;bottom:224px;letter-spacing:-0.01px;}
#t14_122{left:238px;bottom:205px;letter-spacing:-0.01px;}
#t15_122{left:238px;bottom:185px;letter-spacing:-0.01px;}
#t16_122{left:238px;bottom:166px;letter-spacing:-0.01px;}
#t17_122{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_122{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_122{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_122{font-size:21px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_122{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_122{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_122{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_122{font-size:9px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts122" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg122Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg122" style="-webkit-user-select: none;"><object width="908" height="1286" data="122/122.svg" type="image/svg+xml" id="pdf122" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_122" class="t s0_122">8.4. Molecular diagnostics in follow-up care </span><span id="t2_122" class="t s1_122">122 </span>
<span id="t3_122" class="t s2_122">8.4. </span><span id="t4_122" class="t s2_122">Molecular diagnostics in follow-up care </span>
<span id="t5_122" class="t s3_122">8.7. </span><span id="t6_122" class="t s4_122">Consensus-based statement </span>
<span id="t7_122" class="t s5_122">EEC </span>
<span id="t8_122" class="t s4_122">There are no established tumor markers for molecular diagnostics in the follow-up of </span>
<span id="t9_122" class="t s4_122">patients with laryngeal carcinoma. </span>
<span id="ta_122" class="t s6_122">Consensus: 95% </span>
<span id="tb_122" class="t s4_122">Currently, there are no established tumor markers for molecular diagnostics in the follow-up </span>
<span id="tc_122" class="t s4_122">of patients with laryngeal carcinoma that have been validated by sufficiently large </span>
<span id="td_122" class="t s4_122">retrospective and prospective studies. </span>
<span id="te_122" class="t s4_122">Approaches for noninvasive molecular diagnostics in relation to treatment response and early </span>
<span id="tf_122" class="t s4_122">detection of tumor progression currently focus on the analysis of cell-free tumor DNA in saliva </span>
<span id="tg_122" class="t s4_122">or blood samples [428]. The detection of tumor DNA is a sensitive and specific biomarker for </span>
<span id="th_122" class="t s4_122">numerous tumor entities, including head and neck squamous cell carcinoma (HNSCC), and is </span>
<span id="ti_122" class="t s4_122">often independent of the detection of circulating tumor cells in the blood [429]. </span>
<span id="tj_122" class="t s4_122">The potential of detecting tumor DNA in saliva and blood samples was tested in a study with 93 </span>
<span id="tk_122" class="t s4_122">HNSCC patients (of which n=10 had laryngeal carcinoma) [428]. Tumor DNA was defined by the </span>
<span id="tl_122" class="t s4_122">detection of viral DNA (HPV16 and HPV18) or frequently occurring somatic mutations in HNSCC. </span>
<span id="tm_122" class="t s4_122">Tumor DNA was detected in 76% of saliva samples and 87% of blood samples. In a subgroup </span>
<span id="tn_122" class="t s4_122">for which both saliva and blood samples were available, the proportion of patients with positive </span>
<span id="to_122" class="t s4_122">tumor DNA findings was 96%. With regard to molecular diagnostics in follow-up care, saliva </span>
<span id="tp_122" class="t s4_122">and blood samples were taken from nine patients after tumor resection and tested for tumor </span>
<span id="tq_122" class="t s4_122">DNA as part of the study. Tumor DNA was detected in three patients (including one patient with </span>
<span id="tr_122" class="t s4_122">laryngeal carcinoma) several months before a clinical finding of tumor progression. In contrast, </span>
<span id="ts_122" class="t s4_122">no tumor DNA was detected in saliva or blood samples in patients without tumor progression. </span>
<span id="tt_122" class="t s4_122">In another study on resistance mechanisms during treatment with cetuximab, tumor DNA </span>
<span id="tu_122" class="t s4_122">from blood samples of 20 HNSCC patients (mainly from the oral cavity and oropharynx) was </span>
<span id="tv_122" class="t s4_122">examined [430]. The data show an enrichment of activating RAS mutations in patients with </span>
<span id="tw_122" class="t s4_122">progression during the course of therapy. In half of the patients, RAS mutations were already </span>
<span id="tx_122" class="t s4_122">detected before the diagnosis of clinical progression. </span>
<span id="ty_122" class="t s4_122">An alternative for molecular diagnostics in the follow-up of laryngeal carcinoma is the detection </span>
<span id="tz_122" class="t s4_122">of circulating tumor cells (CTCs) in blood samples. The detection of CTCs during or after </span>
<span id="t10_122" class="t s4_122">treatment can indicate a high risk of treatment failure and tumor progression. A meta-analysis </span>
<span id="t11_122" class="t s4_122">of published studies on HNSCC shows that the detection of CTCs in the blood has a high </span>
<span id="t12_122" class="t s4_122">specificity but only a low sensitivity as a diagnostic biomarker and is associated with poor </span>
<span id="t13_122" class="t s4_122">progression-free and overall survival [431]. In a prospective study, CTCs in blood samples from </span>
<span id="t14_122" class="t s4_122">53 HNSCC patients (including 15 with laryngeal carcinoma) with local recurrence or distant </span>
<span id="t15_122" class="t s4_122">metastasis were examined before and after systemic therapy [432]. CTCs could be detected in </span>
<span id="t16_122" class="t s4_122">30% of the patients and were significantly correlated with the prognosis and treatment efficacy. </span>
<span id="t17_122" class="t s0_122">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
